Cochlear (FRA:OC5) Accounts Payable: €160 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OC5 Cochlear Ltd FRA:OC5
74 GF Score
Price €74.53
GF Value €188.34
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Cochlear Accounts Payable?

Cochlear FRA:OC5 +1.36% 74 Accounts Payable is €160 Mil as of Dec. 2025. GuruFocus rates FRA:OC5 with a GF Score™ of 74/100 and a GF Value™ of €188.34 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Cochlear's Accounts Payable for the quarter that ended in Dec. 2025 was €160 Mil.

Cochlear's quarterly Accounts Payable declined from Dec. 2024 (€173 Mil) to Jun. 2025 (€168 Mil) and declined from Jun. 2025 (€168 Mil) to Dec. 2025 (€160 Mil).

Cochlear's annual Accounts Payable increased from Jun. 2023 (€168 Mil) to Jun. 2024 (€187 Mil) but then declined from Jun. 2024 (€187 Mil) to Jun. 2025 (€168 Mil).

Cochlear Accounts Payable Historical Data

* Premium members only.

The historical data trend for Cochlear's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cochlear Accounts Payable Chart

Cochlear Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.75 154.50 167.50 187.03 168.43

Cochlear Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 151.67 187.03 172.67 168.43 159.62
FRA:OC5
74GF Score
Cochlear Ltd FRA:OC5
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cochlear Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €160 Mil mean?
Cochlear (FRA:OC5) has a Accounts Payable of €160 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cochlear and its competitors.
Is Cochlear's Accounts Payable too high?
Cochlear's current Accounts Payable is €160 Mil. Overall, Cochlear has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Accounts Payable compare to ABT and SYK?
Cochlear's Accounts Payable of €160 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cochlear and its competitors. Cochlear's current Accounts Payable is €160 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (FRA:OC5) is currently considered Significantly Undervalued. The stock's GF Value™ is €188.34, compared to a current price of €74.53 — trading 60.4% below its estimated fair value. The current Accounts Payable is €160 Mil. Cochlear's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Cochlear (FRA:OC5), the current Accounts Payable is €160 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cochlear (FRA:OC5) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of €74.53 is trading 60.4% below its estimated GF Value™ of €188.34. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for FRA:OC5:

  • Accounts Payable: €160 Mil
  • GF Value™: €188.34 vs. price of €74.53 (60.4% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the FRA:OC5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
74GF Score

Get the complete analysis for FRA:OC5

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€74.53
Price
€188.34
GF Value